Patrick John Finn Sells 229 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 229 shares of Twist Bioscience stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $45.59, for a total value of $10,440.11. Following the completion of the sale, the chief operating officer now directly owns 274,466 shares of the company’s stock, valued at $12,512,904.94. This trade represents a 0.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total value of $496,320.00.
• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total transaction of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total transaction of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The shares were sold at an average price of $43.09, for a total transaction of $97,426.49.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $45.12 on Friday. The company has a market capitalization of $2.68 billion, a P/E ratio of -12.53 and a beta of 1.85. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The company’s 50 day moving average price is $46.26 and its two-hundred day moving average price is $46.47.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. increased its holdings in Twist Bioscience by 210.2% during the 2nd quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock worth $6,057,000 after purchasing an additional 83,287 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Twist Bioscience by 215.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after buying an additional 20,035 shares during the period. Barclays PLC grew its holdings in shares of Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after buying an additional 104,420 shares in the last quarter. FMR LLC raised its position in Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after buying an additional 12,327 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in Twist Bioscience by 128.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after acquiring an additional 21,357 shares in the last quarter.

Analyst Ratings Changes

TWST has been the topic of a number of analyst reports. Scotiabank increased their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. Evercore ISI increased their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners boosted their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Robert W. Baird increased their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday, November 19th. Finally, Wolfe Research began coverage on shares of Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.